DK1032556T3 - Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder - Google Patents

Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder

Info

Publication number
DK1032556T3
DK1032556T3 DK98957349T DK98957349T DK1032556T3 DK 1032556 T3 DK1032556 T3 DK 1032556T3 DK 98957349 T DK98957349 T DK 98957349T DK 98957349 T DK98957349 T DK 98957349T DK 1032556 T3 DK1032556 T3 DK 1032556T3
Authority
DK
Denmark
Prior art keywords
methods
compounds
active compounds
pharmaceutically active
treatment
Prior art date
Application number
DK98957349T
Other languages
Danish (da)
English (en)
Inventor
Graham J Durant
Seetharamaiyer Padmanabhan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1032556T3 publication Critical patent/DK1032556T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • C07C323/44X or Y being nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/90Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98957349T 1997-10-21 1998-10-20 Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder DK1032556T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6483097P 1997-10-21 1997-10-21
PCT/US1998/022309 WO1999020599A1 (en) 1997-10-21 1998-10-20 Pharmaceutically active compounds and methods of use

Publications (1)

Publication Number Publication Date
DK1032556T3 true DK1032556T3 (da) 2008-03-25

Family

ID=22058507

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957349T DK1032556T3 (da) 1997-10-21 1998-10-20 Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder

Country Status (10)

Country Link
EP (1) EP1032556B1 (de)
JP (1) JP2001520215A (de)
KR (1) KR20010031065A (de)
AT (1) ATE381533T1 (de)
AU (1) AU1362699A (de)
CA (1) CA2307597A1 (de)
DE (1) DE69838882T2 (de)
DK (1) DK1032556T3 (de)
ES (1) ES2297897T3 (de)
WO (1) WO1999020599A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20021046A1 (es) 2000-09-30 2002-12-14 Gruenenthal Chemie Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina
MXPA03002594A (es) * 2000-10-30 2003-06-30 Warner Lambert Co Ligandos de amidinourea del receptor de serotonina y composiciones, sus usos farmaceuticos y procedimientos para su sintesis.
GB0219472D0 (en) 2002-08-21 2002-10-02 Astrazeneca Ab Chemical compounds
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
NZ568459A (en) 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
ITTO20030668A1 (it) 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.
CA2542419C (en) 2003-10-15 2013-06-04 Probiodrug Ag Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
DK1713780T3 (da) * 2004-02-05 2012-05-07 Probiodrug Ag Hidtil ukendte inhibitorer af glutaminylcyklase
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
MXPA06002391A (es) * 2004-02-20 2006-06-20 Astellas Pharma Inc Derivados de fluoreno.
US20080161419A1 (en) * 2004-02-20 2008-07-03 Shinobu Akuzawa Prophylactic Antimigraine Agents
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
CN101243046A (zh) 2005-08-08 2008-08-13 安斯泰来制药有限公司 酰基胍衍生物或其盐
WO2007022964A2 (de) * 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JP5157892B2 (ja) 2006-02-20 2013-03-06 アステラス製薬株式会社 アミド誘導体またはその塩
CN101627013A (zh) * 2007-02-07 2010-01-13 安斯泰来制药有限公司 酰基胍衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222375A1 (en) * 1973-03-20 1974-10-18 Ugine Kuhlmann 5-Substd guanidino barbituric acids - intermediates prepd from a cyanamide and a uramil
GB1431589A (en) * 1973-07-13 1976-04-07 Smith Kline French Lab Ureas, thioureas and guanidines n,n-disubstituted by heterocyclo- alkylene and/or heterocycloalkylenethioalkylene groups
US3972872A (en) * 1974-09-23 1976-08-03 Pfizer Inc. 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids
DE2531343A1 (de) * 1975-07-14 1977-02-10 Henkel & Cie Gmbh Antimikrobielle mittel
DE2545647C3 (de) * 1975-10-11 1982-03-11 Bayer Ag, 5090 Leverkusen Stabilisierung synthetischer Polymerer
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
FI772270A7 (de) * 1976-08-03 1978-02-04 Sandoz Ag
DE2802757A1 (de) * 1978-01-23 1979-07-26 Sandoz Ag Benz eckige klammer auf cd eckige klammer zu indolyl-derivate, ihre verwendung und herstellung
DE3261340D1 (en) * 1981-04-09 1985-01-10 Beiersdorf Ag Substituted benzo(de)isoquinolines, processes for their preparation, and their application as pharmaceutical preparations
WO1995020950A1 (en) * 1994-02-03 1995-08-10 Cambridge Neuroscience, Inc. Therapeutic guanidines

Also Published As

Publication number Publication date
WO1999020599A1 (en) 1999-04-29
JP2001520215A (ja) 2001-10-30
EP1032556A4 (de) 2005-02-02
CA2307597A1 (en) 1999-04-29
AU1362699A (en) 1999-05-10
DE69838882D1 (de) 2008-01-31
KR20010031065A (ko) 2001-04-16
EP1032556A1 (de) 2000-09-06
EP1032556B1 (de) 2007-12-19
ES2297897T3 (es) 2008-05-01
ATE381533T1 (de) 2008-01-15
DE69838882T2 (de) 2008-12-04

Similar Documents

Publication Publication Date Title
EP1032556A4 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
NO20045323L (no) Antistoffer
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
PT705100E (pt) Guanidinas substituidas terapeuticas
NO961326L (no) Inhibitorer av -amyloidproteinproduksjon
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE69837809D1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
UY26130A1 (es) Compuestos para tratar la obesidad
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
YU23102A (sh) Jedinjenja za lečenje ishemije
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
MY124786A (en) Bis-arylsulfones
SE9604348D0 (sv) Användning av hydroxyguanidiner
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
AU6469401A (en) Pharmaceutically active compounds and methods of use
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension